Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Share News (VRP)

  • There is currently no data for VRP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monday broker round-up UPDATE

Mon, 11th Nov 2013 08:50

Associated British Foods: Barclays downgrades to equal-weight with a target price of 2100p.Bovis Homes Group: Deutsche Bank moves target price from 1001p to 1008p maintaining a buy recommendation.British Land: Deutsche Bank downgrades to sell with a target price of 520p.British Sky Broadcasting: Nomura reduces target price from 1040p to 850p and downgrades from buy to reduce. Goldman Sachs cuts target price from 1120p to 1070p, while reiterating its buy recommendation.BT Group: JP Morgan increases target price from 380p to 420p upgrading from neutral to overweight. Citi ups target price from 400p to 430p retaining a buy recommendation. UBS cuts target price from 310p to 290p and stays with its sell recommendation.Cable & Wireless Communications: Jefferies shifts target price from 45p to 48p and retains a hold recommendation.Carr's Milling: Investec places both its target price (prev.: 1710p) and its buy recommendation under review.Cobham: Investec cuts target price from 275p to 230p retaining its sell recommendation.Dignity: Investec raises target price from 1562p to 1583p and upgrades from add to buy.Faroe Petroleum: Panmure Gordon moves target price from 182p to 188p and retains a buy recommendation. Westhouse Securities shifts target price from 175p to 185p and maintains a buy recommendation.FlyBe: Liberum Capital initiates with a target price of 90p and a buy recommendation.Gemfields: Investec moves target price from 30p to 37.5p and reiterates a buy recommendation.International Consolidated Airlines Group: Citi raises target price from 380p to 535p and stays with its buy recommendation. HSBC takes target price from 405p to 420p maintaining an overweight rating. Credit Suisse increases target price from 345p to 443p and reiterates an outperform rating.International Personal Finance: RBC Capital shifts target price from 700p to 695p and maintains an outperform rating.ITV: Citi ups target price from 180p to 191p, while downgrading from buy to neutral. Goldman Sachs lowers target price from 240p to 237p and retains a buy recommendation.Lonmin: Investec places its target price (prev.: 266p), while leaving its sell recommendation unaltered.Morgan Advanced Materials: Investec places its target price (prev.: 410p) under review, while keeping its buy recommendation.Paragon Group: RBC Capital ups target price from 350p to 390p upgrading to outperform.Rentokil Initial: JP Morgan moves target price from 75p to 86p, while leaving its underweight rating unchanged.Royal Bank of Scotland: Jefferies raises target price from 390p to 441p and keeps a buy recommendation.RSA Insurance Group: Citi reduces target price from 146p to 126p downgrading from buy to neutral. Panmure Gordon moves target price from 98p to 117p, but still recommends selling. Credit Suisse lowers target price from 125p to 110p and downgrades to underperform.Shire: Panmure Gordon raises target price from 2850p to 3100p and keeps a buy recommendation.Tullett Prebon: UBS cuts target price from 315p to 290p and maintains its sell recommendation.Verona Pharma: N+1 Singer initiates with a target price of 5.1p and a buy recommendation.Wincanton: Investec ups target price from 75p to 122p, while downgrading from buy to hold.
More News
7 Mar 2019 11:28

DIRECTOR DEALINGS: Verona Pharma Chair David Ebsworth Buys Shares

LONDON (Alliance News) - Clinical-stage biopharmaceutical company Verona Pharma PLC said on Thursday Chair David Ebsworth bought 26,300 shares for 56.30 pence each on Wednesday.Following in

Read more
4 Mar 2019 13:35

Monday broker round-up

(Sharecast News) - RSA Insurance Group: JP Morgan downgrades to neutral with a target price of 610p.

Read more
4 Mar 2019 10:12

Verona Pharma Reports Positive Data From Lung Disease Treatment Trial

LONDON (Alliance News) - Shares in Verona Pharma PLC rose on Monday following positive data from part of a Phase Two clinical trial of a dry powder inhaler formulation of Verona's ensifentrine

Read more
14 Jan 2019 10:23

WINNERS & LOSERS SUMMARY: JD Sports Rises After Strong Christmas

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - LOSERS----------Paddy Power

Read more
14 Jan 2019 09:47

Verona Pharma's Ensifentrine COPD Study Does Not Meet Primary Endpoint

LONDON (Alliance News) - Verona Pharma PLC on Monday said its phase two clinical trial of nebulized Ensifentrine did not meet its primary endpoint but did perform better than placebo.Shares

Read more
14 Jan 2019 08:48

Verona Pharma shares plunge on latest drug trial results

(Sharecast News) - Verona Pharma shares were well into the red on Monday, after the clinical-stage biopharmaceutical company announced top-line data from its latest trial of RPL554, failing to reach its primary endpoint.

Read more
9 Jan 2019 15:44

Verona Pharma granted WHO approval for Ensifentrine name

(Sharecast News) - Clinical stage biopharmaceutical outfit Verona Pharma has been granted approval of the name Ensifentrine for its first-in-class, inhaled, dual inhibitor drug candidate RPL554 by the World Health Organisation.

Read more
17 Dec 2018 14:22

Verona Pharma initiates Phase 2 study of RPL554

(Sharecast News) - Clinical-stage biopharmaceutical company Verona Pharma announced the initiation of a Phase 2 clinical trial to evaluate the pharmacokinetic (PK) profile, efficacy and safety of a dry powder inhaler (DPI) formulation of 'RPL554', in patients with moderate to severe chronic obstructive pulmonary disease (COPD), on Monday.

Read more
6 Nov 2018 11:56

Verona Pharma Third-Quarter Loss Narrows On Finance Income

LONDON (Alliance News) - Verona Pharma PLC on Tuesday said its loss narrowed by two thirds in the third quarter of 2018 on increased finance income and reduced costs as it initiated a phase two of

Read more
31 Oct 2018 12:25

Verona Pharma Completes Enrollment In Clinical Trial Of RPL554

LONDON (Alliance News) - Verona Pharma PLC said Wednesday it has completed the enrollment for its Phase 2 clinical trial evaluating the effect of nebulised RPL554 as an add-on to dual therapy in a

Read more
26 Oct 2018 11:46

Verona Pharma turns in positive data from RPL554 trials

(Sharecast News) - Clinical-stage biopharmaceutical company Verona Pharma turned in some positive data from its pre-clinical and Phase 2a trials on its potential cystic fibrosis treatment RPL554.

Read more
1 Aug 2018 12:49

Verona Pharma Starts Phase 2 Trial For Respiratory Disease Treatment

LONDON (Alliance News) - Verona Pharma PLC said Wednesday that it started the second phase of a clinical trial of its nebulized RPL554 drug for the treatment of patients with chronic obstructive 2

Read more
8 May 2018 07:01

LONDON MARKET EARLY CALL: Stocks Called Lower As Iran Fears Boost Oil

LONDON (Alliance News) - Stock prices in London are seen opening lower on Tuesday following Monday's UK bank holiday as Chinese exports recovered at a faster pace in April amid concerns the US

Read more
26 Mar 2018 10:19

Verona Pharma Shares Rise As It Gets Good Results From RPL554 Trials

LONDON (Alliance News) - Verona Pharma PLC said Monday it has received positive top-line data from its phase 2b study for its proposed RPL554 treatment.RPL554 is a for

Read more
8 Mar 2018 13:59

DIRECTOR DEALINGS: Verona Pharma CEO Karlsson Buys 3,250 Shares

LONDON (Alliance News) - Verona Pharma PLC, a clinical-stage biopharmaceutical company, said Thursday that Chief Executive Officer Jan-Anders Karlsson purchased 3,250 ordinary

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.